Researchers Report New Findings on Metastatic Castration-Resistant Prostate Cancer Treatment Resistance

Researchers Report New Findings on Metastatic Castration-Resistant Prostate Cancer Treatment Resistance
A recent study on metastatic castration-resistant prostate cancer (mCRPC) showed that androgen receptor V7 (or AR-V7) status has no significant impact on the response to taxane chemotherapy. The study entitled “AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC)” was presented during the 2015 Genitourinary Cancers Symposium held

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *